Abstract: Disclosed herein is a system for facilitating fast and intuitive investigations of security incidents by responding to physical gestures performed by security analysts within a virtual scene. A query triggers an alert for detecting security incidents that occur with respect to computing resources. Following the alert, the security analyst dons a Near-Eye-Display (NED) device and is presented with a virtual scene having control elements representing various data sets and/or data analysis operations relevant to a security incident. The security analyst investigates the security incident by performing hand motions to “grab-and-drag” control elements representing data sets. The security analyst may also perform hand motions to “tap on” control elements that represents a data analysis operation. Responsive to the hand motions, the system performs data analysis operations and displays a result within the virtual scene.

Abstract: This disclosure is directed to vehicle fuel systems that include door opening modules for controlling a fuel door opening sequence. An exemplary door opening module may include an actuator (e.g., a motor, an electromagnet, a solenoid, etc.) for automatically moving the fuel door to an ajar position after a fuel tank depressurization sequence is completed. Sound messages may be communicated to a user during the depressurization sequence by an audio actuator.

Abstract: The storage of events of multiple types in a queriable table. The queriable table has at least one common column that corresponds to a field that is common across events regardless of event type. The queriable table also has at least one field-varying column that corresponds to a type-dependent field that depends on event type. The queriable table is populated using multiple events. For instance, the event could be at least some log events that are received from multiple computing systems. The population occurs by assigning each event to a row of the queriable table. The common column is populated with values taken the same common field across event types. On the other hand, the field-varying column is populated with values of different fields from those events depending on the event type.

Abstract: The present invention provides compounds of Formula (I). wherein A and Z are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

Abstract: An aqueous anti-dandruff shampoo composition which comprises: (I) a cleansing surfactant selected from the group consisting of anionic surfactant, zwitterionic or amphoteric surfactant and nonionic surfactant; (II) suspended particles of an anti-dandruff agent, (III) an anti-settling, thickening polymer, wherein the anti-settling, thickening polymer, comprises: (a) 40 to 74.5 wt % of structural units of C1-4 alkyl acrylate; (b) 20 to 50 wt % of structural units of methacrylic acid; (c) 0.

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

Abstract: The present invention provides compounds of Formula (I); wherein the substituents are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

Abstract: This disclosure is directed to vehicle fuel systems that include door opening modules for controlling a fuel door opening sequence. An exemplary door opening module may include an actuator (e.g., a motor, an electromagnet, a solenoid, etc.) for automatically moving the fuel door to an ajar position after a fuel tank depressurization sequence is completed. Sound messages may be communicated to a user during the depressurization sequence by an audio actuator.

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

Abstract: This disclosure relates to a fuel or charging port door assembly of a motor vehicle. In particular, this disclosure relates to a fuel or charging port door assembly configured to permit a door to open when an override force is applied using an assist tool, for example. An example vehicle includes a door configured to move relative to a body of the vehicle between open and closed positions. The door is a fuel door or a charging port door. The vehicle also includes a lock assembly including a base and a tip. The base is configured to hold the tip during normal operating conditions, and the base and tip are configured to separate upon application of an override force to the door.

Abstract: An anti-settling, thickening polymer is provided for use in an acidic aqueous cleansing formulation having a pH of <5, wherein the anti-settling, thickening polymer, comprises: (a) structural units of C1-4 alkyl acrylate; (b) structural units of methacrylic acid; (c) structural units of 2-acrylamido-2-methylpropane sulfonic acid (AMPS); (d) structural units of a specialized associated monomer having the following structure wherein R1 is a linear saturated C10-24 alkyl group; wherein R2 is a hydrogen or a methyl; and wherein n is an average of 20 to 28; (e) structural units of acrylic acid; and (f) structural units of multi-ethylenically unsaturated crosslinking monomer or chain transfer agent; and wherein the sum of the weight percentages of structural units (a)-(f) is equal to 100 wt % of the anti-settling, thickening polymer. Also provided are acidic aqueous cleansing formulations containing same.

Abstract: The present invention provides compounds of Formula (I). wherein A and Z are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

Abstract: The present invention provides compounds of Formula (I); wherein the substituents are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

Abstract: An acidic aqueous shampoo composition, which comprises: (I) a cleansing surfactant selected from the group consisting of anionic surfactant, zwitterionic or amphoteric surfactant and nonionic surfactant; (II) an emulsified silicone, (III) an anti-settling, thickening polymer, wherein the anti-settling, thickening polymer, comprises: (a) 40 to 74.5 wt % of structural units of C1-4 alkyl acrylate; (b) 20 to 50 wt % of structural units of methacrylic acid; (c) 0.

Abstract: The invention provides a personal cleansing composition comprising, in an aqueous continuous phase: (i) from 5 to 30% by weight of one or more anionic cleansing surfactants; (ii) from 0.1 to 10% by weight of discrete, dispersed droplets of emulsified silicone with a mean diameter (D3,2) of 4 micrometres or less; (iii) from 0.1 to 5% by weight of microcapsules in which a core comprising benefit agent is encapsulated in a polymeric shell, and (iv) from 0.1 to 0.5% by weight of a combination of cationic polymers comprising: (a) at least one cationic polygalactomannan derivative having a mean charge density at pH 7 from 0.2 to 2 meq per gram; and (b) at least one acrylamidopropyltrimonium chloride/acrylamide copolymer having a mean charge density at pH 7 from 1 to 3 meq per gram.

Abstract: A mobile device includes one or more electronic circuits that control the operation of the device. The electronic circuit can be connected to a power source by a switch that can be maintained in the open position when the device is being shipped and stored prior to use. The act of taking the mobile device out of the package can include manipulating the mobile device to cause the switch to close connecting the electronic circuit to the power source to begin operation. In accordance with some embodiments, the switch can include a magnetic switch that is maintained in the open position by a magnetic component in the packaging and becomes closed when the mobile device is removed from the packaging. In accordance with some embodiments, the switch can be maintained in the open position by a packaging insert and becomes closed when the package is opened removing the insert.

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

Abstract: A non-invasive thermal dispersion flow meter with chronometric monitor for fluid leak detection includes a heater, an ambient temperature sensor and a flow rate sensor which are configured to sense the temperature of a fluid in a conduit, and then monitor the flow of that fluid through the conduit. Based upon the ambient temperature sensor readings, the flow rate sensor and heater may be adjusted to optimize the operation of the system to detect leaks. Based on the sensor readings, the flow may be adjusted to prevent damage and leaks by relieving the system of excess pressure. Geographic location, occupancy sensors and occupant identifiers are used to control the system to facilitate operation and minimize leak damage when occupants are away.

Abstract: The invention provides a method of assessing the potential color protecting effect in vivo of a test formulation such as rinse-off hair treatment formulation, the method comprising the steps of: providing a sample of the test formulation to be assessed; providing a model substrate in the form of a hair switch which has been artificially colored; applying the test formulation to the hair switch; subsequently rinsing the test formulation from the hair switch; collecting the rinse liquor and analysing it for the presence of eluted color; characterized in that the artificial color used to color the hair switch is a permanent hair colorant with a shade level 1 or 2 according to the International Color Chart (I.C.C.). The method provides improved sensitivity and differentiation, and enables the tester to compare different technologies in terms of effectiveness.